79 Delayed-Onset Muscle Soreness (Doms)-a New Pain Model to Compare Otc Analgesics

R, Braun; Lockhart, E-a.; Pochulu, Bruno

doi:10.1249/00005768-199405001-00080

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…third molar extraction, sore throat, postpartum episiotomy pain, tension-type headache, and delayed-onset muscle soreness). 3 – 7 These studies also demonstrated that IBU is safe and well tolerated.…”

mentioning

confidence: 71%

Onset of Analgesia and Efficacy of Ibuprofen Sodium in Postsurgical Dental Pain

Brain

Leyva

Doyle

et al. 2015

The Clinical Journal of Pain

View full text Add to dashboard Cite

Objectives:A novel, immediate-release tablet formulation of ibuprofen (IBU) sodium dihydrate, Advil Film Coated Tablets (IBUNa), has been developed that is absorbed faster than standard IBU tablets. The objective of the current study was to compare the efficacy and onset of analgesia of this new formulation with standard IBU tablets after a single dose.Materials and Methods:Patients (N=316) with at least moderate baseline postsurgical dental pain were randomized to 400 mg IBUNa, Advil (IBUAdv), Motrin (IBUMot), or placebo. Primary endpoints were time-weighted sum of pain relief (PR) and pain intensity differences over 8 hours (SPRID 0-8) and time to onset of meaningful pain relief (TMPR) measured by the double-stopwatch method.Results:SPRID 0-8 was significantly greater for IBUNa and the other active treatments versus placebo (P<0.001). IBUNa had a significantly earlier TMPR versus placebo, pooled IBUAdv/IBUMot, and IBUMot (P<0.001 for all), and a marginally faster TMPR (P=0.075) versus IBUAdv. Results for secondary endpoints were similar. Adverse events were comparable across treatment groups, with gastrointestinal disorders being most frequently reported. Most adverse events were mild or moderate.Discussion:This novel formulation of IBUNa provided superior overall PR compared with placebo and more rapid onset of analgesic effect compared with standard IBU tablets. Rapid PR is important in the treatment of acute pain, including dental pain, and this IBUNa formulation represents a new treatment option for rapid PR.

show abstract

mentioning

confidence: 71%

Onset of Analgesia and Efficacy of Ibuprofen Sodium in Postsurgical Dental Pain

Brain

Leyva

Doyle

et al. 2015

The Clinical Journal of Pain

View full text Add to dashboard Cite

show abstract

“…53 The DERP reviews are updated at least annually, and are subject to peer review and public comment before final publication. 54 These sources were sufficient for evaluating most claims, but for six claims, the coders were provided with additional references: publications from head-to-head trials comparing acetaminophen to ibuprofen, [55][56][57][58][59][60][61] IMS Health data from 2008 to evaluate a claim of prescription popularity, 62 nonprescription label information for a discontinued product from an archived web page, 63,64 links to specific nonprescription drug product labels to evaluate the incipient ingredients in the product, 65,66 and a press release providing up-to-date information to support an advertising claim. 67 We only used publicly available evidence to evaluate claims and did not make requests to pharmaceutical companies for unpublished or "on-file" evidence.…”

Section: Coding: Evaluating the Truthfulness Of The Major Claimmentioning

confidence: 99%

Content Analysis of False and Misleading Claims in Television Advertising for Prescription and Nonprescription Drugs

Faerber

Kreling

2013

J GEN INTERN MED

View full text Add to dashboard Cite

BACKGROUND: False and misleading advertising for drugs can harm consumers and the healthcare system, and previous research has demonstrated that physician-targeted drug advertisements may be misleading. However, there is a dearth of research comparing consumer-targeted drug advertising to evidence to evaluate whether misleading or false information is being presented in these ads. OBJECTIVE: To compare claims in consumer-targeted television drug advertising to evidence, in order to evaluate the frequency of false or misleading television drug advertising targeted to consumers. DESIGN: A content analysis of a cross-section of television advertisements for prescription and nonprescription drugs aired from 2008 through 2010. We analyzed commercial segments containing prescription and nonprescription drug advertisements randomly selected from the Vanderbilt Television News Archive, a census of national news broadcasts. MAIN MEASURES: For each advertisement, the mostemphasized claim in each ad was identified based on claim iteration, mode of communication, duration and placement. This claim was then compared to evidence by trained coders, and categorized as being objectively true, potentially misleading, or false. Potentially misleading claims omitted important information, exaggerated information, made lifestyle associations, or expressed opinions. False claims were factually false or unsubstantiated. KEY RESULTS: Of the most emphasized claims in prescription (n=84) and nonprescription (n=84) drug advertisements, 33 % were objectively true, 57 % were potentially misleading and 10 % were false. In prescription drug ads, there were more objectively true claims (43 %) and fewer false claims (2 %) than in nonprescription drug ads (23 % objectively true, 7 % false). There were similar numbers of potentially misleading claims in prescription (55 %) and nonprescription (61 %) drug ads. CONCLUSIONS:Potentially misleading claims are prevalent throughout consumer-targeted prescription and nonprescription drug advertising on television. These results are in conflict with proponents who argue the social value of drug advertising is found in informing consumers about drugs. O ver the past 15 years, drug advertising to consumers has expanded to encompass more products and more channels. Advertising for prescription drugs has become more prevalent, with more products being promoted directly to consumers through traditional ad media such as magazines and television, plus the internet has become an additional means to connect with consumers for both prescription and nonprescription drugs. Drug companies increased their marketing budgets for advertising directly to consumers, particularly for prescription drugs. Prescription drug advertising to consumers totaled $4.8 billion USD in 2009, 1-3 well surpassing consumer promotion for nonprescription products at $3.0 billion USD that year. 4 Also over this time period, patients have become viewed more as consumers of health care, emphasizing shared decisionmaking 5-7 and self-care. [8][9]...

show abstract

Nonprescription Ibuprofen and Acetaminophen in the Treatment of Tension‐Type Headache

Schachtel

Furey

Thoden

1996

The Journal of Clinical Pharma

View full text Add to dashboard Cite

A single-dose, double-blind, randomized clinical trial was conducted to examine the relative analgesic effectiveness of 400 mg of ibuprofen (n = 153), 1,000 mg of acetaminophen (n = 151), and placebo (n = 151) in volunteers with muscle contraction headache. At regular intervals during a 4-hour period, participants evaluated headache pain intensity on a 100-mm visual analog scale and headache pain relief on a six-category scale. Both active agents were significantly different from placebo at all time points and in reducing pain intensity and providing relief of headache overall. Similarly, ibuprofen at 400 mg differed significantly from acetaminophen at 1,000 mg on both rating scales. Participants receiving ibuprofen at 400 mg achieved complete relief of headache faster than those receiving acetaminophen at 1,000 mg or placebo, and more participants taking ibuprofen experienced complete relief of headache than those taking placebo or acetaminophen. Both ibuprofen at 400 mg and acetaminophen at 1,000 mg are efficacious analgesic agents for muscle contraction headache, and ibuprofen at 400 mg is significantly more effective than acetaminophen at 1,000 mg for treating this condition.

show abstract

79 Delayed-Onset Muscle Soreness (Doms)-a New Pain Model to Compare Otc Analgesics

Cited by 3 publications

References 0 publications

Onset of Analgesia and Efficacy of Ibuprofen Sodium in Postsurgical Dental Pain

Onset of Analgesia and Efficacy of Ibuprofen Sodium in Postsurgical Dental Pain

Content Analysis of False and Misleading Claims in Television Advertising for Prescription and Nonprescription Drugs

Nonprescription Ibuprofen and Acetaminophen in the Treatment of Tension‐Type Headache

Contact Info

Product

Resources

About